Pricing Log in Create free account
Friday 6 November 2026 Export XERS’s income statement to Excel — free account

Xeris Biopharma Holdings, Inc.

XERS Healthcare Drug Manufacturers Specialty & Generic

Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.

Revenue
+44.2%
EPS
+1,479.0%
Free cash flow
+93.2%
Total debt
−13.6%

Quarter to September 2026, against a year earlier

15.16 2.08 +15.90%
Market cap
$2.4B
P/E
0.0×
Fwd P/E
−143×
Dividend yield
—
F-score
8/9
Altman Z
0.98
Beneish M
−2.58
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 5.40
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 2 3 1 2 1 1 5 3 3 4 3 3
Insider Ownership 4.33%

Capital & Financial Ratios $m

Size
Market Cap 2,380.00
Revenue ttm 368.26
Net income ttm (6.50)
Free cash flow ttm 73.65
Net debt Q 58.63
Valuation
P/E 0.00
Forward P/E (143.00) (negative: loss-making)
Price / sales 7.45
Forward P/S Powerpack
Price / FCF 37.73
Price / book 56.23 (above 6: high)
Financial health
Current ratio Q 2.15 (at or above 1.5: strong)
Debt / equity Q 3.89 (above 2: weak)
Interest coverage Q 2.62
Growth
Revenue growth Q +44.16% (above 0%: growing)
Operating income growth Q +151.36% (above 0%: growing)
EPS, this year −411.82% (below 0%: weak)
EPS, next year A +3,667.14% (at or above 15%: strong)
Revenue, next year A +32.91% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 7.8×, against a ten-year median of 4.5×; over the ten years it ranged from −23.1× in 2018 to 193× in 2018.
P/S against its own 10 years 64.05%
10-year low 10-year high
P/B against its own 10 years 87.56%
10-year low 10-year high
EV/Sales against its own 10 years 70.25%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 72 72 111 131
Receivables 39 40 51 69
Inventory 39 48 69 77
Other — — — —
156 168 240 289
2023 2024 2025 Q'26
Payables 12 2 3 8
ST’ Debt — 15 — —
Other 20 1 5 4
95 100 110 134

Compound Annual Growth %

10y 5y 3y
Sales — 70.20% 38.33%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (16.52%) (32.84%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 0.02 Actual 0.00

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 0.01 0.00 Miss by 0.01
Q4 FY25 0.03 0.06 Beat by 0.03
Q1 FY26 0.00 0.01 Beat by 0.01
Q2 FY26 0.02 0.00 Miss by 0.02
Q3 FY26 0.02 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 0.01 (0.18) 0.06 — —
’25 (0.06) (0.01) 0.00 0.06 0.00
’24 (0.14) (0.10) (0.11) (0.03) (0.37)
’23 (0.12) (0.14) (0.09) (0.10) (0.45)
’22 (0.25) (0.19) (0.16) (0.10) (0.70)
’21 (0.30) (0.41) (0.39) (0.42) (1.55)
’20 (0.89) (0.63) (0.35) (0.41) (2.14)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 83 92 107 — —
’25 60 72 74 86 292
’24 41 48 54 60 203
’23 33 38 48 44 164
’22 22 25 30 33 110
’21 8 9 11 21 50
’20 2 2 9 7 20
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 10 8 35 — —
’25 (10) 0 18 20 29
’24 (20) (10) (8) 2 (37)
’23 (26) (14) (15) 7 (47)
’22 (48) (21) (18) (16) (103)
’21 (24) (20) (23) (29) (96)
’20 (29) (24) (17) (11) (81)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 10 8 35 — —
’25 (10) 0 18 20 28
’24 (20) (11) (8) 2 (38)
’23 (26) (15) (15) 7 (49)
’22 (48) (21) (18) (16) (103)
’21 (24) (20) (23) (29) (97)
’20 (29) (24) (17) (11) (81)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 1 2 2 3 20 50 110 164 203 292 368 +86.4% 388 480 552 +23.6%
Gross margin, % 99.26 99.74 100.00 41.11 54.35 73.14 79.47 82.52 81.86 85.41 87.38 (13.9) pt
EBT (13) (27) (60) (126) (91) (123) (96) (64) (57) 1 (6) n/m
EBT margin, % (1,228.74) (1,706.56) (2,479.57) (4,630.35) (446.54) (247.48) (87.15) (38.74) (28.12) 0.19 (1.76) +1,228.9 pt
Net income (13) (27) (60) (126) (91) (123) (95) (62) (55) 1 (6) n/m
Per share, $
Per share, $ Revenue 0.58 0.77 0.20 0.10 0.48 0.63 0.81 1.19 1.38 1.82 2.04 +13.5%
Earnings (7.17) (13.09) (4.99) (4.81) (2.14) (1.55) (0.70) (0.45) (0.37) 0.00 (0.04) n/m
Cash flow (8.73) (12.16) (4.67) (4.00) (1.89) (1.21) (0.76) (0.34) (0.25) 0.18 0.41 n/m
Capex (0.02) (0.35) (0.13) (0.04) (0.01) (0.01) 0.00 (0.02) (0.01) 0.00 0.00 (15.2%)
Free cash flow (8.75) (12.51) (4.80) (4.04) (1.90) (1.22) (0.76) (0.36) (0.26) 0.17 0.41 n/m
Book value 16.81 19.75 6.26 0.55 0.79 1.21 0.33 (0.05) (0.20) 0.09 0.27 (44.4%)
Shares, m 2 2 12 26 43 79 136 138 147 160 171 +64.3%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2,065.79 0.00 206.6
P/S 0.00 0.00 84.52 67.63 10.27 4.67 1.38 1.91 2.45 4.32 7.45 17.7
P/B 0.00 0.00 2.72 12.75 6.21 2.43 3.36 0.00 0.00 92.00 56.23 11.9
EV/Sales 0.00 0.00 51.19 62.39 8.13 4.44 1.98 2.64 3.24 4.73 7.78 13.9
EV/FCF (0.35) (0.35) (2.15) (1.61) (2.05) (2.28) (2.11) (8.79) (17.39) 49.43 39.41 1.2
Cash, $m
Cash, $m Operating cash flow (16) (25) (56) (104) (81) (96) (103) (47) (37) 29 74 n/m
Capex 0 (1) (2) (1) 0 (1) (1) (2) (1) (1) (1) +39.4%
Free cash flow (16) (25) (58) (105) (81) (97) (103) (49) (38) 28 74 n/m
Balance, $m
Balance, $m Working capital 31 39 108 60 124 64 113 61 67 131 155 +17.5%
Net debt (32) (42) (81) (17) (47) (14) 67 118 160 109 59 n/m
Shareholders’ equity 31 40 75 14 34 95 45 (7) (30) 14 49 (8.7%)
Returns, %
Returns, % ROA (33.64) (67.63) (72.81) (109.67) (67.98) (52.95) (29.18) (18.66) (16.99) 0.16 (1.64) +33.8 pt
ROIC 0.00 0.00 0.00 0.00 0.00 (89.00) (45.78) (24.63) (16.07) 12.65 27.22 +12.7 pt
ROE 29.43 59.16 (683.66) (279.56) (378.20) (190.28) (134.83) (324.20) 301.32 (6.96) (27.11) (36.4) pt
People
People Employees — 55 90 202 180 294 355 377 394 435 — +29.5%
Revenue/emp, $m 0.00 0.03 0.03 0.01 0.11 0.17 0.31 0.43 0.52 0.67 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Xeris Biopharma Holdings, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AMLX Amylyx Pharmaceuticals, Inc. $3.5B — (loss-making) — (loss-making) −100.61% (below 0%: shrinking) n/m −24.50% (below 0%: shrinking) 100.00% 0.00% Compare
RGC Regencell Bioscience Holdings Limited $2.6B — (loss-making) — — — +57.15% (above 0%: growing) 0.00% — Compare
HCM HUTCHMED (China) Limited Sponsored ADR $2.5B — (loss-making) — +510.07% (above 0%: growing) +419.25% (above 0%: growing) +113.21% (above 0%: growing) 60.90% 0.00% Compare
XERS Xeris Biopharma Holdings, Inc. $2.4B — (loss-making) — (loss-making) +44.16% (above 0%: growing) +1,478.95% (above 0%: growing) +93.18% (above 0%: growing) 88.41% 15.78%
PRGO Perrigo Company plc $2.2B — (loss-making) — (loss-making) −5.24% (below 0%: shrinking) n/m +138.48% (above 0%: growing) 32.45% 2.34% Compare
PBH Prestige Consumer Healthcare Inc. $2.1B 13.2× 11.7× +22.69% (above 0%: growing) −38.07% (below 0%: shrinking) −38.18% (below 0%: shrinking) 51.30% 24.00% Compare
TRLV Trulieve Cannabis Corp. $2.1B — (loss-making) — (loss-making) −20.12% (below 0%: shrinking) n/m +24.49% (above 0%: growing) 64.30% 0.00% Compare
BCRX BioCryst Pharmaceuticals, Inc. $2.0B — (loss-making) — (loss-making) +13.11% (above 0%: growing) +147.17% (above 0%: growing) −18.69% (below 0%: shrinking) 99.13% 29.58% Compare
ALVO Alvotech $1.8B — (loss-making) 111× +2,310.95% (above 0%: growing) −99.51% (below 0%: shrinking) −496.58% (below 0%: shrinking) 56.47% 9.14% Compare
Median of peers $2.1B — — +13.11% +54.55% +2.90% 58.69% 2.34%

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 23 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 5.04m 11.99m 159.55
2023 2.14m 3.46m 47.76
2022 2.81m 1.02m 27.03
2021 3.76m 2.29m 59.55

Ownership

Directors and executive officers, together 4.35%
The Vanguard Group 6.48%
BlackRock, Inc. 5.80%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Xeris Biopharma Holdings, Inc. (XERS) Latest News

6 Nov

Impact 4 · · GuruFocus.com
Impact 3 · · MarketBeat

5 Nov

Impact 4 · · The Motley Fool transcript
Impact 4 · · Stocktwits
Impact 4 · · Business Wire
Impact 3 · · Moby
Impact 3 · · Associated Press

22 Oct

Impact 3 · · Business Wire

15 Oct

Impact 3 · · Business Wire

8 Oct

Impact 4 · · Simply Wall St.

29 Sep

Impact 4 · · Investing.com
Impact 3 · · Stocktwits

9 Sep

Impact 3 ·

15 Aug

Impact 3 ·

14 Aug

Impact 3 ·

13 Aug

Impact 3 · · The Motley Fool transcript

7 Aug

Impact 3 · · MarketBeat transcript

6 Aug

Impact 4 ·
Impact 3 ·
Impact 3 ·

30 Jun

Impact 4 ·

11 Jun

Impact 3 ·

15 May

Impact 3 · · Simply Wall St.

9 May

Impact 4 · · Simply Wall St.
Impact 3 · · MarketBeat

8 May

Impact 4 · · Simply Wall St.
Impact 3 · · Moby

7 May

Impact 4 · · The Motley Fool transcript
Impact 4 · · Zacks
Impact 4 · · Business Wire

XERS metrics, ten years each

stockrow.com/XERS · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com